Search Results - "FARAG, Sherif S"

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect by Benson, Don M., Bakan, Courtney E., Zhang, Shuhong, Collins, Shauna M., Liang, Jing, Srivastava, Shivani, Hofmeister, Craig C., Efebera, Yvonne, Andre, Pascale, Romagne, Francois, Bléry, Mathieu, Bonnafous, Cécile, Zhang, Jianying, Clever, David, Caligiuri, Michael A., Farag, Sherif S.

“…Multiple myeloma (MM) patients who receive killer cell Ig–like receptor (KIR) ligand–mismatched, T cell–depleted, allogeneic transplantation may have a reduced…”
Get full text

Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study by Dhakal, Binod, Zhang, Mei-Jei, Burns, Linda J, Tang, Xiaoying, Meyer, Christa, Mau, Lih-Wen, Nooka, Ajay K, Stadtmauer, Edward, Micallef, Ivana N, McGuirk, Joseph, Costa, Luciano, Juckett, Mark B, Shah, Nina, Champlin, Richard E, Usmani, Saad Z, Farag, Sherif S, Nishihori, Taiga, Roy, Vivek, Bodiford, Andrew, Barnes, Yvonne J, Drea, Edward J, Hari, Parameswaran, Hamadani, Mehdi

Get full text

Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide–CCI-779 Interaction via P-Glycoprotein by HOFMEISTER, Craig C, XIAOXIA YANG, JIA JI, SCHAAF, Larry J, BENSON, Don M, KRAUT, Eric H, HICKS, William J, CHAN, Kenneth K, CHEN, Ching-Shih, FARAG, Sherif S, GREVER, Michael R, BYRD, John C, PICHIORRI, Flavia, PHELPS, Mitch A, PING CHEN, ROZEWSKI, Darlene M, JOHNSON, Amy J, LEE, Seungsoo, ZHONGFA LIU, GARR, Celia L, HADE, Erinn M

“…Multiple myeloma (MM) is an incurable plasma-cell neoplasm for which most treatments involve a therapeutic agent combined with dexamethasone. The preclinical…”
Get full text

KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation by Weisdorf, Daniel, Cooley, Sarah, Wang, Tao, Trachtenberg, Elizabeth, Vierra-Green, Cynthia, Spellman, Stephen, Sees, Jennifer A., Spahn, Ashley, Vogel, Jenny, Fehniger, Todd A., Woolfrey, Ann E., Devine, Steven M., Ross, Maureen, Waller, Edmund K., Sobecks, Ronald M., McGuirk, Joseph, Oran, Betul, Farag, Sherif S., Shore, Tsiporah, Van Besien, Koen, Marsh, Steven G.E., Guethlein, Lisbeth A., Parham, Peter, Miller, Jeffrey S.

“…Natural killer (NK) cell recognition and killing of target cells are enhanced when inhibitory killer immunoglobulin-like receptors (KIR) are unable to engage…”
Get full text

Sitagliptin for Prophylaxis of Acute Graft-versus-Host Disease. Reply by Farag, Sherif S

Get full text

Blood progenitor cell separation from clinical leukapheresis product by magnetic nanoparticle binding and magnetophoresis by Jing, Ying, Moore, Lee R., Williams, P. Stephen, Chalmers, Jeffrey J., Farag, Sherif S., Bolwell, Brian, Zborowski, Maciej

“…Positive selection of CD34+ blood progenitor cells from circulation has been reported to improve patient recovery in applications of autologous…”
Get full text

Histoplasma capsulatum Infection in an Allogeneic Hematopoietic Stem Cell Transplant Patient Receiving Voriconazole Prophylaxis by Agrawal, Vaibhav, Farag, Sherif S., Brinda, Bryan J.

“…Histoplasma capsulatum infection is a rare complication in the allogeneic stem cell transplant patients. Minimal guidance exists on how to appropriately manage…”
Get full text

The impacts of total body irradiation on umbilical cord blood hematopoietic stem cell transplantation by Wang, Hao, Berger, Kristin N., Miller, Elizabeth L., Fu, Wei, Broglie, Larisa, Goldman, Frederick D., Konig, Heiko, Lim, Su Jin, Berg, Arthur S., Talano, Julie-An, Comito, Melanie A., Farag, Sherif S., Pu, Jeffrey J.

“…Background: Umbilical cord blood hematopoietic stem cells are commonly used for hematopoietic system reconstitution in recipients after umbilical cord blood…”
Get full text

Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD‐2076, against multiple myeloma by Wang, Xiaojing, Sinn, Anthony L., Pollok, Karen, Sandusky, George, Zhang, Shuhong, Chen, Li, Liang, Jing, Crean, Colin D., Suvannasankha, Attaya, Abonour, Rafat, Sidor, Carolyn, Bray, Mark R., Farag, Sherif S.

“…Summary ENMD‐2076 is a novel, orally‐active molecule that has been shown to have significant activity against aurora and multiple receptor tyrosine kinases. We…”
Get full text

The potential role of Aurora kinase inhibitors in haematological malignancies by Farag, Sherif S.

“…Summary Aurora kinases play an important role in the control of the cell cycle and have been implicated in tumourigenesis in a number of cancers. Among the…”
Get full text

OSU-03012, a Novel Celecoxib Derivative, Is Cytotoxic to Myeloma Cells and Acts through Multiple Mechanisms by SHUHONG ZHANG, SUVANNASANKHA, Attaya, CREAN, Colin D, WHITE, Valerie L, JOHNSON, Amy, CHEN, Ching-Shih, FARAG, Sherif S

“…Purpose: OSU-03012 is a novel celecoxib derivative, without cyclooxygenase-2 inhibitory activity, capable of inducing apoptosis in various cancer cells types,…”
Get full text

Outcome of Induction and Postremission Therapy in Younger Adults With Acute Myeloid Leukemia With Normal Karyotype: A Cancer and Leukemia Group B Study by FARAG, Sherif S, RUPPERT, Amy S, STAMBERG, Judith, BAER, Maria R, BLOCK, Annemarie W, VARDIMAN, James W, KOLITZ, Jonathan E, SCHIFFER, Charles A, LARSON, Richard A, BLOOMFIELD, Clara D, MROZEK, Krzysztof, MAYER, Robert J, STONE, Richard M, CARROLL, Andrew J, POWELL, Bayard L, MOORE, Joseph O, PETTENATI, Mark J, KODURU, Prasad R. K

“…Evaluate the outcome of induction and postremission therapy in adults younger than 60 years with normal cytogenetics acute myeloid leukemia (AML). In 490…”
Get full text

Antimyeloma Effects of a Sesquiterpene Lactone Parthenolide by SUVANNASANKHA, Attaya, CREAN, Colin D, SHANMUGAM, Rajasubramaniam, FARAG, Sherif S, ABONOUR, Rafat, BOSWELL, H. Scott, NAKSHATRI, Harikrishna

“…Purpose: Nuclear factor-κB (NF-κB), activated in multiple myeloma (MM) cells by microenvironmental cues, confers resistance to apoptosis. The sesquiterpene…”
Get full text

Biology and clinical impact of human natural killer cells by FARAG, Sherif S, VANDEUSEN, Jeffrey B, FEHNIGER, Todd A, CALIGIURI, Michael A

“…Natural killer (NK) cells, through elaboration of cytokines and cytolytic activity, are critical to host defense against invading organisms and malignant…”
Get full text

Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease by Farag, Sherif S, Abu Zaid, Mohammad, Schwartz, Jennifer E, Thakrar, Teresa C, Blakley, Ann J, Abonour, Rafat, Robertson, Michael J, Broxmeyer, Hal E, Zhang, Shuhong

“…Sitagliptin is a selective inhibitor of dipeptidyl peptidase 4. Among 36 patients undergoing allogeneic hematopoietic stem-cell transplantation treated with…”
Get full text

Human natural killer cell development and biology by Farag, Sherif S., Caligiuri, Michael A.

“…Natural killer cells are important innate immune effector cells with potentially broad applications in the treatment of human malignancy due to their ability…”
Get full text

Effect of family cohesion on symptom distress during hematopoietic stem cell transplantation by Yang, Yesol, Pan, Wei, Farag, Sherif S., Von Ah, Diane

“…Purpose Family may play an important role in hematopoietic stem cell transplantation (HSCT) recovery; however, little is known about the effect of family…”
Get full text

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma by Benson, Don M., Hofmeister, Craig C., Padmanabhan, Swaminathan, Suvannasankha, Attaya, Jagannath, Sundar, Abonour, Rafat, Bakan, Courtney, Andre, Pascale, Efebera, Yvonne, Tiollier, Jérôme, Caligiuri, Michael A., Farag, Sherif S.

“…Natural killer (NK) cells elicit cytotoxicity against multiple myeloma (MM); however, MM cells express HLA class I molecules as ligands to NK cell inhibitory…”
Get full text

A phase 2 trial of CD24Fc for prevention of graft-versus-host disease by Magenau, John, Jaglowski, Samantha, Uberti, Joseph, Farag, Sherif S, Riwes, Mary Mansour, Pawarode, Attaphol, Anand, Sarah, Ghosh, Monalisa, Maciejewski, John, Braun, Thomas, Devenport, Martin, Lu, Susan, Banerjee, Bhramori, DaSilva, Carolyn, Devine, Steven, Zhang, Mei-Jie, Burns, Linda J, Liu, Yang, Zheng, Pan, Reddy, Pavan

“…Patients who undergo human leukocyte antigen-matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative…”
Get full text

Age is no barrier for adults undergoing HCT for AML in CR1: contemporary CIBMTR analysis by Maakaron, Joseph E., Zhang, Mei-Jie, Chen, Karen, Abhyankar, Sunil, Bhatt, Vijaya Raj, Chhabra, Saurabh, El Jurdi, Najla, Farag, Sherif S., He, Fiona, Juckett, Mark, de Lima, Marcos, Majhail, Navneet, van der Poel, Marjolein, Saad, Ayman, Savani, Bipin, Ustun, Celalettin, Waller, Edmund K., Litzow, Mark, Kebriaei, Partow, Hourigan, Christopher S., Saber, Wael, Weisdorf, Daniel

“…Acute Myeloid Leukemia (AML) has a median age at diagnosis of 67 years. The most common curative therapy remains an allogeneic hematopoietic stem cell…”
Get full text